Sichuan Huiyu Pharmaceutical Co., Ltd

This study tests an experimental drug called HY05350 in people with advanced solid tumors that have a specific protein called MSLN. The goal is to find safe doses and see if the drug can shrink tumors. About 262 adults who have not responded to standard treatments will take part.

This study tests a new drug, HY07121, in 258 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe, tolerable, and can shrink tumors. Participants receive the drug by infusion, and the study will monitor side effe…

This study tests a new drug called HY0001a in 261 adults with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study is in two parts: first to check safety and dosing, then to measure h…

This early-phase study tests a new drug called HYP-6589 in people with advanced solid tumors (including a type of lung cancer). The study has two parts: first, finding a safe dose of HYP-6589 alone; second, testing it combined with other targeted drugs. About 115 adults with tumo…

This study checks if a generic version of the chemotherapy drug paclitaxel works the same as the brand-name version in people with breast cancer. About 24 patients will receive both versions at different times to compare drug levels in their blood. The goal is to ensure the gener…

This study tests an experimental drug called HYP-2090PTSA in people with advanced solid tumors that have a KRAS mutation. The goal is to find a safe dose and see if the drug can shrink tumors. About 257 adults will take part in two phases: first to check safety, then to measure e…

This early-stage study tests a new drug called HY-2003, which is injected under the chin to reduce excess fat (double chin). About 30 adults with moderate to severe submental fullness will receive either the new drug, a similar approved drug, or a placebo. The main goal is to che…